Regen BioPharma Past Earnings Performance

Past criteria checks 0/6

Regen BioPharma has been growing earnings at an average annual rate of 20.8%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 19.9% per year.

Key information

20.8%

Earnings growth rate

45.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate19.9%
Return on equityn/a
Net Margin-327.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Regen BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:RGBP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-100
30 Sep 230110
30 Jun 230110
31 Mar 2306810
31 Dec 220110
30 Sep 220200
30 Jun 220100
31 Mar 220-6700
31 Dec 210-600
30 Sep 210-700
30 Jun 210-400
31 Mar 210600
31 Dec 200200
30 Sep 200300
30 Jun 200400
31 Mar 200-410
31 Dec 190010
30 Sep 190-310
30 Jun 190-510
31 Mar 190-110
31 Dec 180-210
30 Sep 180-510
30 Jun 180-511
31 Mar 180-811
31 Dec 170-812
30 Sep 170-611
30 Jun 170-521
31 Mar 170-421
31 Dec 160-321
30 Sep 160-321
30 Jun 160-321
31 Mar 160-321
31 Dec 150-320
30 Sep 150-220
30 Jun 150-220
31 Mar 150-110
31 Dec 140-110
30 Sep 140-110
30 Jun 140-110
31 Mar 140-100
31 Dec 130000

Quality Earnings: RGBP is currently unprofitable.

Growing Profit Margin: RGBP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RGBP is unprofitable, but has reduced losses over the past 5 years at a rate of 20.8% per year.

Accelerating Growth: Unable to compare RGBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: RGBP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.